CD23: An overlooked regulator of allergic disease

Daniel H. Conrad, Jill W. Ford, Jamie L. Sturgill, David R. Gibb

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations

Abstract

Given the importance of immunoglobulin (Ig) E in mediating type I hypersensitivity, inhibiting IgE production would be a general way of controlling allergic disease. The low-affinity IgE receptor (FcεRII or CD23) has long been proposed to be a natural regulator of IgE synthesis. In vivo research supporting this concept includes the observation that mice lacking CD23 have increased IgE production whereas mice overexpressing CD23 show strongly suppressed IgE responses. In addition, the finding that mice injected with monoclonal antibody directed against the coiled-coil stalk of CD23 have enhanced soluble CD23 release and increased IgE production demonstrates that full-length, trimeric CD23 is responsible for initiating an IgE inhibitory signal. The recent identification of ADAM10 (a disintegrin and metalloprotease) as the CD23 metalloprotease provides an alternative approach for designing therapies to combat allergic disease. Current data suggest that stabilizing cell-surface CD23 would be a natural means to decrease IgE synthesis and thus control type I hypersensitivity.

Original languageEnglish
Pages (from-to)331-337
Number of pages7
JournalCurrent Allergy and Asthma Reports
Volume7
Issue number5
DOIs
StatePublished - Sep 2007

Bibliographical note

Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'CD23: An overlooked regulator of allergic disease'. Together they form a unique fingerprint.

Cite this